Circulating tumour cells and cell-free DNA as tools for managing breast cancer
- 28 May 2013
- journal article
- review article
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 10 (7) , 377-389
Abstract
Circulating blood biomarkers promise to become non-invasive real-time surrogates for tumour tissue-based biomarkers. Circulating biomarkers have been investigated as tools for breast cancer diagnosis, the dissection of breast cancer biology and its genetic and clinical heterogeneity, prognostication, prediction and monitoring of therapeutic response and resistance. Circulating tumour cells and cell-free plasma DNA have been analysed in retrospective studies, and the assessment of these biomarkers is being incorporated into clinical trials. As the scope of breast cancer intratumour genetic heterogeneity unravels, the development of robust and standardized methods for the assessment of circulating biomarkers will be essential for the realization of the potentials of personalized medicine. In this Review, we discuss the current status of blood-born biomarkers as surrogates for tissue-based biomarkers, and their burgeoning impact on the management of patients with breast cancer.Keywords
This publication has 120 references indexed in Scilit:
- The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancerBreast Cancer Research and Treatment, 2012
- Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patientsArchives of Gynecology and Obstetrics, 2011
- The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancerBreast Cancer Research and Treatment, 2011
- Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technologyBreast Cancer Research and Treatment, 2011
- CA 15-3: Uses and limitation as a biomarker for breast cancerClinica Chimica Acta, 2010
- HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trialBreast Cancer Research and Treatment, 2010
- Use of cancer‐specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumorsGenes, Chromosomes and Cancer, 2010
- Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancerBreast Cancer, 2009
- Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patientsBreast Cancer Research and Treatment, 2009
- Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapiesBreast Cancer Research and Treatment, 2008